To include your compound in the COVID-19 Resource Center, submit it here.

CeNeS hurries to grow

Growing companies through in-licensing marketed products has not always been successful: such products are often pharmaceutical company cast-offs at the end of their life cycle. But CeNeS Pharmaceuticals plc, which just acquired three pain killing products from Glaxo Wellcome plc, believes having a pharmaceuticals division is a vital component

Read the full 492 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE